A CDSCO oncology medical device license is mandatory under India's Medical Devices Rules, 2017 for any manufacturer or importer of notified oncology devices — including brachytherapy systems, alternating electric field antimitotic cancer treatment systems, flexible fibreoptic bronchoscopes and colonoscopes, cancer risk assessment software, and radiotherapy applicators. Oncology devices span Class A through Class D. Manufacturing Class A and B devices requires a Form MD5 license from the State Licensing Authority (fee: Rs. 5,000 plus Rs. 500 per device). Manufacturing Class C and D devices requires a Form MD9 license from CDSCO Central (fee: Rs. 50,000 plus Rs. 1,000 per device). Importing any class requires a Form MD15 import license from CDSCO. All three license types are valid indefinitely, subject to a retention fee paid every 5 years — non-payment results in automatic cancellation. Applications are submitted through the CDSCO SUGAM portal (cdscoonline.gov.in). ISO 13485 certification and a comprehensive Device Master File are mandatory for all manufacturing license applications.
Oncology is the branch of medicine concerned with the prevention, diagnosis, treatment, and monitoring of cancer. The medical devices that support oncological care span an extraordinary range — from non-invasive clinical support equipment and screening instruments to highly specialised radiotherapy systems, brachytherapy applicators, and implantable devices that deliver cancer therapy directly to tumour tissue. Across this spectrum, oncology medical devices carry an acute clinical responsibility: they are used in the care of patients with life-threatening conditions, and their performance, accuracy, and safety are inseparable from clinical outcomes.
India's oncology landscape is undergoing significant transformation. The country's rising cancer burden, combined with expanding government and private investment in cancer diagnosis and treatment infrastructure, is generating growing demand for oncology devices at every level of the healthcare system — from district cancer screening programmes to tertiary cancer centres deploying advanced radiotherapy technology. For manufacturers and importers entering this segment, understanding CDSCO's licensing framework — the classification system, the applicable license types, and the document and application requirements — is the essential foundation for a compliant, commercially viable market entry in India.
📑 Quick Navigation
- Demand for Oncology Medical Devices in India
- CDSCO Regulations: Why Mandatory Compliance Matters
- CDSCO Classification: Oncology Devices by Class
- Mandatory Documents for CDSCO Oncology Device License
- Three CDSCO License Types: MD5, MD9, MD15
- 5-Step Application Process Through CDSCO SUGAM
- License Validity and Retention Fee Requirements
- 5 Benefits of CDSCO Licensing for Oncology Device Manufacturers
- How Rego Services Supports Your CDSCO Application
- Frequently Asked Questions
Demand for Oncology Medical Devices in India
India's oncology medical device market is expanding against the backdrop of one of the world's most significant cancer burdens. With over 1.4 million new cancer cases registered annually and a growing proportion of the population reaching the age groups most at risk for cancer, demand for oncology diagnostic, therapeutic, and monitoring devices is rising sharply across both government and private healthcare channels. India is now among the highest-burden countries globally for cancers of the breast, cervix, lung, head and neck, and gastrointestinal tract — each requiring a distinct set of oncology devices for screening, staging, treatment, and surveillance.
The government's National Cancer Mission and National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS) have structurally increased public sector demand for oncology diagnostic equipment — including flexible endoscopes, bronchoscopes, colonoscopes, and cancer risk assessment systems — deployed at cancer screening camps and district-level screening programmes across the country. Simultaneously, the rapid expansion of dedicated cancer hospitals, comprehensive cancer centres, and oncology departments at private tertiary hospitals is generating capital procurement demand for radiotherapy systems, brachytherapy equipment, endoscopic platforms, and surgical oncology instruments at a scale that was not present a decade ago.
The growing adoption of minimally invasive surgical oncology — including endoscopic tumour resection, laparoscopic oncology surgery, and bronchoscopic interventions — is driving consistent demand for flexible fibreoptic and video endoscopes, bronchoscopes, colonoscopes, and mediastinoscopes across oncology surgical suites. For device companies entering this segment with a valid CDSCO license, the addressable market spans government cancer programme procurement, private hospital capital equipment decisions, and ongoing consumable and accessory supply across a broad spectrum of oncology specialities and cancer types.
CDSCO Regulations: Why Mandatory Compliance Matters
The clinical environment in which oncology medical devices are deployed — cancer surgery, radiotherapy, brachytherapy, endoscopic diagnosis, and systemic therapy administration — demands the highest standard of device performance, safety, and reliability. A brachytherapy system that delivers an inaccurate radiation dose, a flexible bronchoscope that provides a compromised image during a diagnostic procedure for a suspected lung malignancy, or an alternating electric field cancer treatment system with inconsistent field delivery characteristics carries consequences that go directly to patient outcomes in the care of cancer patients.
CDSCO's regulatory framework for oncology medical devices under the Medical Devices Rules, 2017 is built on this recognition. By requiring manufacturers and importers to obtain a CDSCO license, demonstrate ISO 13485-certified quality management systems, and submit comprehensive Device Master Files with device-specific performance and safety data, CDSCO ensures that every notified oncology device entering the Indian market has been assessed against a defined quality and safety standard. For manufacturers and importers, a valid CDSCO license is not a discretionary compliance measure — it is a mandatory legal prerequisite for placing oncology devices on the Indian market, without which manufacture or import is not lawfully permitted.
CDSCO Classification: Oncology Devices by Class
The Medical Devices Rules, 2017 classify all notified medical devices into four risk-based classes — A (lowest risk) through D (highest risk). For oncology devices, this classification spans the complete risk spectrum, reflecting the clinical diversity of oncology medicine — from environmental support equipment to precision energy-delivery systems used in active cancer treatment. Determining the correct CDSCO class for your specific oncology device is the mandatory first step that determines which license form applies, which authority issues the license, and the fee structure that governs the application.
- Capsular tension ring
- Blepharoplasty scissors
- Brachytherapy radionuclide phantom, anthropomorphic
- Antimicrobial postsurgical female underpants
- Antimicrobial postsurgical brassière
- Extravascular-circulation hyperthermia system applicator, extracorporeal
- Eye brachytherapy system applicator, manual
- Cytotoxic waste receptacle
- Cervical cytology scraper, reusable
- Breast binder
- Bladder instillation buffer solution
- Acupressure wristband
- Externally-propelled flexible video colonoscope
- Facial prosthesis
- Flexible fibreoptic bronchoscope
- Flexible fibreoptic colonoscope
- Class-I biological safety cabinet
- Brachytherapy system chair
- Brachytherapy system remote afterloading source transfer tube
- Activated-oxygen generator
- Alternating electric field antimitotic cancer treatment system generator
- Alternating electric field antimitotic cancer treatment system transducer array
- Brachytherapy needle
- Breast 3-D infrared imaging / vascular analysis system
- Cancer risk assessment interpretive software
- Endocervical aspirator
- Electronic clinical breast examination system
- Accelerator system operator console
- Bile duct brachytherapy system applicator, remote-afterloading
- Flexible fibreoptic mediastinoscope
- Class-II biological safety cabinet
- Cervical cone knife
- Brachytherapy system remote afterloading source safe
- Brachytherapy system remote afterloading operator console
- Electro cancer therapy system
- Alternating electric field antimitotic cancer treatment system
- Extravascular-circulation hyperthermia system
- Extravascular-circulation hyperthermia system applicator, intracorporeal
- Flexible ultrasound bronchoscope
- Coronary artery brachytherapy system applicator, manual afterloading
- Breast transilluminator
- Brain brachytherapy system applicator, manual
- Brain brachytherapy system applicator, remote-afterloading
Mandatory Documents for CDSCO Oncology Device License Application
To apply for a CDSCO oncology medical device license, applicants must compile a defined set of supporting documents. The quality, completeness, and internal consistency of this document set is the primary factor that determines how efficiently the application progresses through CDSCO review — and, for Class C and D oncology devices, through expert committee scrutiny and facility inspection. For Class D oncology devices such as brain brachytherapy applicators and alternating electric field cancer treatment systems, the technical depth of the Device Master File is especially critical.
- Organisation identity proof — Certificate of Incorporation, Memorandum and Articles of Association, GST registration certificate, and other applicable documents establishing the legal identity and standing of the applicant company. All documents must consistently reflect the same registered entity name and address.
- Sale Deed or Rent Deed of the premises — Valid documentary evidence confirming the applicant's legal right to occupy the declared manufacturing premises. The address on this document must match precisely the facility address declared in the Plant Master File and on the SUGAM application form.
- Building layout with dimensions — An accurate, dimensioned floor plan of the manufacturing facility showing all production areas, quality control laboratory, raw material and finished-goods storage zones, personnel areas, and product flow routes. For oncology devices with radiation components or biological safety requirements, the layout must clearly indicate controlled and restricted areas, shielded zones, and biological safety cabinet locations where applicable.
- Plant Master File (PMF) — A comprehensive document describing the manufacturing facility: location, layout, equipment list and calibration records, manufacturing process flows, environmental monitoring provisions, quality control procedures, personnel structure, GMP compliance infrastructure, and storage conditions. For Class C and D oncology devices — including brachytherapy systems, alternating electric field generators, and intracorporeal hyperthermia systems — the PMF must demonstrate rigorous GMP compliance, appropriate radiation safety protocols, and the calibration infrastructure needed to verify device performance.
- Device Master File (DMF) — The comprehensive technical dossier for the oncology device: device description and intended use, design documentation, materials specification and biocompatibility assessment (ISO 10993 where relevant), manufacturing process description, risk management file under ISO 14971, performance and safety testing data against applicable standards (IEC 60601-1, IEC 60601-2-11 for gamma beam therapy, IEC 60601-2-64 for light ion beam therapy, IEC 60601-2-17 for brachytherapy, and others as applicable), software validation records where the device incorporates software functions, labelling and Instructions for Use, and post-market surveillance plan. For Class D oncology devices delivering energy or radiation to cancer tissue, the DMF must address dose accuracy, treatment field characterisation, and clinical safety evidence with supporting test data from accredited laboratories.
- Documents for the team of qualified and experienced staff — Curriculum vitae, educational qualifications, appointment letters, and training records for personnel responsible for manufacturing and testing the oncology devices, demonstrating CDSCO's minimum qualification requirements are met for technical and quality roles. For devices with radiation components, radiation safety officer credentials and relevant regulatory authorisations must be included.
- Environmental regulation compliance documents — Applicable Pollution Control Board No-Objection Certificate and waste disposal documentation. This is particularly relevant for oncology device manufacturers dealing with cytotoxic materials, biological waste from testing activities, or radioactive sources used in brachytherapy systems — each of which is subject to specific regulatory compliance requirements beyond the standard PCB framework.
- ISO 13485 Certificate — A current, valid certificate from an IAF-accredited certification body, with scope explicitly covering the manufacturing activities relevant to the oncology device being licensed. For sterile oncology device manufacturers, the scope must specifically include sterile medical device manufacturing. For manufacturers of radiation-delivering devices, the scope must cover the relevant device categories.
- Certificate of Analysis for 3 consecutive production batches — Laboratory analysis and performance test results demonstrating that three sequential production batches consistently meet all declared specifications. For first-time manufacturers, these batches must be produced under a valid CDSCO MD13 test license before the MD5 or MD9 application can proceed.
- Test License (if required) — Where initial production batches were manufactured under an MD13 test license prior to the permanent license application, a copy of that license must be included as a supporting document contextualising the submitted batch data.
For Class C oncology devices — brachytherapy needles, alternating electric field generator and transducer components, cancer risk assessment software, bile duct brachytherapy applicators, and electro cancer therapy systems — and especially for Class D devices including full alternating electric field antimitotic cancer treatment systems, brain brachytherapy applicators, and intracorporeal hyperthermia systems — the Device Master File receives the most intensive CDSCO scrutiny. The dose accuracy, energy delivery characterisation, software validation, and long-term safety evidence sections of the DMF must be prepared with specialist input and fully supported by testing data from accredited laboratories. Gaps in safety and performance evidence for energy-delivering and radiation-delivering oncology devices are the most common cause of expert committee queries.
CDSCO Medical Device Test License (MD13 / MD17) India 2026 — Complete Guide
If you are a first-time manufacturer of oncology medical devices, you will need to produce a Certificate of Analysis for three consecutive production batches before applying for the MD5 or MD9 permanent manufacturing license. An MD13 test license is the legally required prerequisite for manufacturing these initial batches. This guide covers the complete test license process — mandatory documents, the SUGAM application, and validity rules.
Three CDSCO License Types: MD5, MD9, MD15
Three distinct CDSCO license types apply to oncology medical devices — determined by whether the applicant is manufacturing or importing, and, for manufacturers, the risk class of the specific device being licensed.
Manufacturing Class A and B oncology devices — such as brachytherapy radionuclide phantoms, flexible fibreoptic bronchoscopes, externally-propelled video colonoscopes, and brachytherapy chairs — requires an MD5 license from the State Licensing Authority of the state in which the facility is located, with a base fee of Rs. 5,000 plus Rs. 500 per distinct device. Manufacturing Class C and D oncology devices — such as alternating electric field antimitotic cancer treatment system generators, brachytherapy needles, brain brachytherapy applicators, and intracorporeal hyperthermia systems — requires an MD9 license from CDSCO's Central Licensing Authority, with a base fee of Rs. 50,000 plus Rs. 1,000 per distinct device. Importing oncology devices of any class into India requires an MD15 import license from CDSCO regardless of the device's risk classification.
5-Step Application Process Through CDSCO SUGAM
The CDSCO oncology medical device license application follows a defined five-step process, filed entirely through the CDSCO SUGAM online portal at cdscoonline.gov.in. Selecting the correct form — MD5, MD9, or MD15 — based on the confirmed device classification is a prerequisite to beginning the application.
Compile all mandatory supporting documents: organisation identity proof, Sale Deed or Rent Deed of the premises, dimensioned building layout, Plant Master File, Device Master File, qualified personnel documentation, environmental compliance certificates, Certificate of Analysis for three consecutive batches, ISO 13485 certificate, and MD13 test license where applicable. Every document must be internally consistent — the device's intended use in the DMF must match the form declaration exactly, the facility layout must correspond to the PMF, and personnel records must align with qualifications declared in the application. For Class D oncology devices such as brain brachytherapy applicators and alternating electric field systems, the performance and safety testing data in the DMF must be from accredited laboratories and must address the specific technical parameters CDSCO's expert committees evaluate for these categories.
File the application online at cdscoonline.gov.in, selecting the applicable license form — MD5 (Class A/B manufacture), MD9 (Class C/D manufacture), or MD15 (import all classes). Complete all fields accurately, attach all supporting documents in the specified file formats and within the portal's size limits, and pay the applicable government fee. Fee payment formally submits the application — prior to payment, the application remains in draft status and has not been received by the licensing authority. Retain the application reference number generated on submission for all subsequent correspondence with CDSCO.
CDSCO may raise written queries on the submitted application and documents through the SUGAM portal — typically relating to the Device Master File's technical content, the ISO 13485 certificate's scope coverage, or the completeness of batch Certificate of Analysis data. For Class C and D oncology devices such as brachytherapy systems, alternating electric field cancer treatment system generators, and intracorporeal hyperthermia applicators, queries from CDSCO expert committees relating to energy delivery accuracy, radiation safety data, and clinical evidence are common. All queries must be addressed promptly and accurately through the SUGAM portal, with supporting documentary evidence. Assign a regulatory lead to monitor the portal daily for query notifications, since response timelines directly affect the overall application timeline.
For MD5 and MD9 manufacturing license applications, CDSCO regulatory officials may conduct a facility inspection to verify that the manufacturing processes, quality management systems, personnel qualifications, and facility infrastructure declared in the Plant Master File and Device Master File are accurate and operationally in place. For Class C and D oncology device manufacturers — particularly those producing brachytherapy systems, alternating electric field cancer treatment systems, and intracorporeal hyperthermia devices — the inspection will cover radiation safety protocols, calibration records for test and measurement equipment, software validation evidence, and GMP compliance across the full manufacturing process. Conduct a rigorous pre-inspection internal audit using the PMF as the primary inspection checklist.
Once all CDSCO criteria are satisfied — all documents verified, queries resolved, and inspection findings (where applicable) cleared — the applicable oncology medical device license is granted through the SUGAM portal: Form MD5, MD9, or MD15. Review the license details carefully on receipt to confirm that every device name, facility address, and applicant entity name is accurately reflected. Any discrepancies should be flagged to the issuing authority immediately for correction before commencing commercial manufacture or import activity under the license.
License Validity and Retention Fee Requirements
The CDSCO oncology medical device license is valid indefinitely from the date of grant — there is no fixed expiry date on the license itself. This indefinite validity provides long-term regulatory stability for manufacturers and importers who have built their commercial operations around a licensed oncology device portfolio.
| Parameter | MD5 — Class A/B Manufacture | MD9 — Class C/D Manufacture | MD15 — Import All Classes |
|---|---|---|---|
| Validity | Indefinite | Indefinite | Indefinite |
| Retention fee cycle | Every 5 years | Every 5 years | Every 5 years |
| Effect of non-payment | Automatic cancellation | Automatic cancellation | Automatic cancellation |
| Issuing authority | State Licensing Authority | CDSCO (Central) | CDSCO (Central) |
| Initial license fee | Rs. 5,000 + Rs. 500/device | Rs. 50,000 + Rs. 1,000/device | Class-dependent |
5 Benefits of CDSCO Licensing for Oncology Device Manufacturers
A valid CDSCO license is the legal gateway to India's oncology medical device market — a market structurally driven by a rising cancer burden, expanding National Cancer Mission infrastructure, growing private hospital oncology investment, and increasing adoption of minimally invasive surgical and diagnostic oncology procedures. Without a valid CDSCO license, neither manufacture nor import of notified oncology devices is legally permissible in India. Obtaining the license converts the country's growing oncology demand into legally accessible commercial opportunity.
Oncologists, radiation oncologists, and hospital procurement committees are exceptionally vigilant about the quality and regulatory status of the devices used in cancer care settings. CDSCO licensing — backed by ISO 13485 quality management certification and comprehensive Device Master File documentation — signals that a manufacturer's brachytherapy systems, alternating electric field treatment devices, or bronchoscopes have been assessed against a verified safety and performance standard, supporting trust-based commercial relationships in a high-stakes speciality.
India's National Cancer Mission and state cancer screening programmes procure oncology devices through government and empanelled hospital channels. CDSCO licensing is a mandatory eligibility requirement for government procurement participation. Manufacturers with a valid MD5 or MD9 license gain access to this substantial public procurement channel — covering flexible endoscopes, cancer screening systems, and diagnostic equipment deployed through the national cancer screening network — while unlicensed competitors are excluded regardless of product quality.
Oncology devices imported without a valid CDSCO MD15 license face customs detention and potential seizure. For cancer hospitals dependent on continuous supply of brachytherapy consumables, bronchoscope accessories, or replacement components for radiotherapy systems, customs delays directly affect clinical operations and patient care schedules. A valid MD15 license ensures consistent, uninterrupted customs clearance — protecting the supply continuity that oncology departments depend on.
Oncology device demand in India is structurally durable — driven by demographic trends, expanding healthcare access, government cancer mission investment, and rising incidence that are independent of short-term economic cycles. A CDSCO license with indefinite validity provides the long-term regulatory foundation from which manufacturers can grow their oncology device portfolio — adding new endoscopic systems, brachytherapy products, or cancer diagnostic instruments through variation applications as the business scales.
CDSCO General Hospital Medical Device License India 2026 — Complete Guide
Oncology device manufacturers whose portfolio also includes general hospital equipment — patient monitoring systems, infusion devices, surgical tables, or sterilisation equipment used across clinical departments — should review the CDSCO licensing requirements for the general hospital device category. These requirements apply alongside oncology-specific licensing and may enable consolidation of multi-category product portfolios under a coordinated licensing strategy.
How Rego Services Supports Your CDSCO Application
Securing the CDSCO oncology medical device license is a technically demanding undertaking — particularly for Class C devices such as brachytherapy system components, alternating electric field generators, and cancer risk assessment software, and especially for Class D devices including brain brachytherapy applicators, intracorporeal hyperthermia systems, and full alternating electric field antimitotic cancer treatment systems, where the technical depth of the Device Master File and the intensity of the Central Licensing Authority's expert committee review require considerable regulatory and technical expertise. Rego Services Private Limited provides end-to-end support for CDSCO oncology medical device license applications across all device classes and all three license types.
- Device classification confirmation and licensing strategy — We confirm the CDSCO class of your specific oncology device configuration — including the critical distinction between extracorporeal (Class A) and intracorporeal (Class D) variants of the same device type — identify the correct license type (MD5, MD9, or MD15), and assess whether an MD13 test license is required before the permanent license application, structuring the pathway correctly from the outset.
- ISO 13485 certification support — Where ISO 13485 certification is not yet in place, we support the full certification process — QMS gap analysis, documentation development, implementation support, and certification body coordination — on a timeline aligned with the CDSCO license application, with scope language correctly covering the oncology device manufacturing activities and, where applicable, sterile device manufacturing and radiation-related manufacturing processes.
- Device Master File preparation — We prepare CDSCO-compliant Device Master Files for oncology devices across all classes, with particular attention to the energy delivery characterisation and dose accuracy data for Class C and D brachytherapy and alternating electric field systems, the software validation documentation for cancer risk assessment and operator console devices, the biocompatibility assessment for devices with body contact, and the clinical safety evidence required for Class D permanently implanted and intracorporeal oncology devices.
- Plant Master File preparation — We prepare Plant Master Files that accurately describe the manufacturing facility in the level of detail CDSCO reviewers and inspectors expect — including GMP compliance evidence, equipment calibration records, radiation safety protocols where applicable, and process validation documentation appropriate for the risk class of the oncology device being licensed.
- Batch production and Certificate of Analysis support — We support the planning, documentation, and coordination of the three consecutive production batch runs and their performance testing required as mandatory evidence for MD5 and MD9 applications.
- SUGAM portal submission management — We manage the complete online application process — form selection, field completion, document upload in the correct format, fee payment coordination, and formal submission — eliminating procedural errors that delay the review clock starting.
- Query response and facility inspection preparation — We draft responses to CDSCO reviewer and expert committee queries — including the technically demanding queries common for Class C and D oncology device applications — and prepare manufacturing facilities for CDSCO inspection through mock inspection exercises that reflect documented inspection patterns for oncology device applications across all device classes.
- Post-grant compliance and retention fee management — We maintain retention fee compliance calendars and support ongoing CDSCO compliance after license grant, helping manufacturers and importers avoid the automatic cancellation risk associated with missed retention fee deadlines, and managing license variation applications as oncology device portfolios expand.
Frequently Asked Questions
Why is the alternating electric field antimitotic cancer treatment system classified as Class D — the highest CDSCO risk category?
The alternating electric field antimitotic cancer treatment system is classified as Class D because it delivers alternating electric fields at low intensity directly to tumour tissue — including in the brain — to disrupt cancer cell division. As an active therapeutic system delivering energy directly to the patient's body in the treatment of life-threatening cancer, any failure in field delivery accuracy, transducer array performance, or generator output carries consequences for oncological treatment efficacy that cannot be readily corrected. This combination of direct energy delivery to the patient, therapeutic intent in the context of cancer treatment, and the critical nature of treatment accuracy places it in CDSCO's highest risk tier, requiring an MD9 license from the Central Licensing Authority and the most rigorous documentation including energy delivery characterisation data and clinical safety evidence.
Can a single MD9 license cover multiple Class C oncology devices — for example, a brachytherapy needle and a cancer risk assessment software system?
Yes. A single MD9 license can cover multiple Class C and D oncology devices, provided each product is separately declared in the Form MD9 application and the Device Master File contains a product-specific section for each device — since a brachytherapy needle and a cancer risk assessment software system are entirely different device types with different intended uses, performance specifications, and applicable standards. Each additional device declared in the application attracts the per-device fee of Rs. 1,000. Adding new Class C or D oncology devices after the initial MD9 is granted requires a variation application to CDSCO Central, not a fresh license application.
What performance testing standards apply to brachytherapy systems for the CDSCO MD9 application?
Brachytherapy systems must comply with applicable IEC and ISO standards referenced under MDR 2017 — including IEC 60601-1 (General requirements for basic safety and essential performance of medical electrical equipment), IEC 60601-2-17 (Particular requirements for the basic safety and essential performance of automatically-controlled brachytherapy afterloading equipment), and IEC 60601-2-38 for remote-afterloading systems where applicable, alongside ISO standards for brachytherapy source characterisation. Testing must be performed by accredited testing laboratories, and the test reports must be included in the Device Master File submitted with the MD9 application. Rego Services advises on the current applicable standards for each Class C and D oncology device category as part of the DMF preparation process.
Does importing flexible fibreoptic bronchoscopes for oncology use require the same MD15 license as importing a Class D intracorporeal hyperthermia applicator?
Yes — both require a valid MD15 import license from CDSCO regardless of their different risk classes (the flexible fibreoptic bronchoscope is Class B; the intracorporeal hyperthermia applicator is Class D). However, different risk classes carry different fee structures under the MD15 pathway, so confirm the applicable fee for each specific device before submitting the import license application. If your import portfolio spans multiple oncology device types and classes, all devices can be covered under a single MD15 license provided each is declared as a separate product entry with its own product-specific documentation.
How does India's National Cancer Mission affect demand for licensed oncology device manufacturers?
The National Cancer Mission is creating a substantial and expanding government procurement pipeline for oncology diagnostic and therapeutic equipment — including flexible endoscopes, cancer risk assessment systems, bronchoscopes, and screening devices deployed through district cancer screening networks and comprehensive cancer centres. This procurement is exclusively available to manufacturers holding valid CDSCO licenses. For companies that have already secured MD5 or MD9 licenses for their oncology device portfolio, the Mission creates access to a growing government tender market that complements private hospital sales. For companies without a valid license, this procurement channel is entirely inaccessible regardless of device quality.
✓ Key Takeaways
- Demand for oncology medical devices in India is rising sharply, driven by a growing cancer burden exceeding 1.4 million new cases annually, the National Cancer Mission, expanding private oncology hospital infrastructure, and increasing adoption of minimally invasive oncology procedures
- Oncology devices span all four CDSCO risk classes — from cytotoxic waste receptacles and brachytherapy phantoms (Class A) through flexible bronchoscopes and colonoscopes (Class B), brachytherapy needles and alternating electric field system generators (Class C), to complete alternating electric field antimitotic cancer treatment systems and brain brachytherapy applicators (Class D)
- Three license types apply: MD5 (manufacture Class A/B — State Licensing Authority, Rs. 5,000 + Rs. 500/device), MD9 (manufacture Class C/D — CDSCO Central, Rs. 50,000 + Rs. 1,000/device), and MD15 (import all classes — CDSCO Central)
- All three license types are valid indefinitely — but the retention fee must be paid every 5 years, or the license is automatically cancelled without the possibility of reinstatement through late payment
- ISO 13485 certification and a comprehensive Device Master File — with particular emphasis on energy delivery accuracy, radiation safety data, and clinical safety evidence for Class C and D oncology devices — are mandatory for all manufacturing license applications
- The CDSCO application process follows 5 structured steps: document preparation, SUGAM portal submission, query resolution, facility inspection (for manufacturing licenses), and license approval
- First-time manufacturers needing initial batch data will require an MD13 test license before applying for the permanent MD5 or MD9 license — this must be factored into the overall regulatory timeline
- A single MD5 or MD9 license can cover multiple oncology devices across the applicable class — new products added after license grant require a variation application to the issuing authority
Your Next Step
Oncology medical devices occupy a clinically and commercially critical position in India's healthcare system — serving a large and growing patient population across cancer diagnosis, treatment, surgical oncology, radiotherapy, and palliative care. The CDSCO licensing framework reflects this importance: the classification system is detailed, the document requirements are demanding — particularly for Class C and D devices delivering energy or radiation in the treatment of cancer — and the license type and issuing authority are determined by the specific risk class of each device. For manufacturers and importers approaching this market, getting the regulatory pathway right from the outset — confirming device classification, structuring the license application correctly, and preparing comprehensive, technically rigorous documentation — is the foundation of a compliant, efficient market entry.
Rego Services' regulatory team brings deep familiarity with CDSCO's requirements across the full oncology device spectrum — from Class A brachytherapy phantoms and Class B flexible bronchoscopes through Class C brachytherapy system components and cancer risk assessment software to Class D alternating electric field antimitotic cancer treatment systems and brain brachytherapy applicators. With our support, the path from device classification through ISO 13485 certification, Device Master File and Plant Master File preparation, SUGAM portal submission, and license grant is a structured, well-managed process rather than the complex and technically demanding challenge it can be without experienced regulatory guidance.
Contact Rego Services today to confirm your oncology device's CDSCO classification, identify the correct license type, and receive a device-specific regulatory plan with a realistic timeline for your India market entry.